Spine BioPharma

About:

Spine BioPharma develops a non-surgical solution for back pain that eliminates pain and restores functionality.

Website: https://www.spinebiopharma.com

Top Investors: Viscogliosi Brothers, Cercano Management, Pacira Pharmaceuticals, Vulcan Capital

Description:

Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improve the lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life.

Total Funding Amount:

$38.3M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

New York, New York, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)SpineBiopharma.com

Founders:

Marc R. Viscogliosi

Number of Employees:

11-50

Last Funding Date:

2023-10-11

IPO Status:

Private

Industries:

© 2025 bioDAO.ai